To elucidate the molecular mechanisms underlying the frequent mutation of Cdkn2a in the early stage of DSS tumor development, we focused on changes in Cdkn2a expression, which is a marker for senescence signaling. This evidence concerns the gene CDKN2A and neoplasm.